{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:13:53Z","timestamp":1793654033411,"version":"4.5.1"},"reference-count":32,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Considering treatment changes and an improved prognosis of non-Hodgkin lymphoma (NHL) over time, knowledge regarding long-term health outcomes, including late effects of treatment, has become increasingly important. We report on time trends of second primary malignancies (SPMs) in Swedish NHL patients, encompassing the years before as well as after the introduction of anti-CD20 antibody therapy. We identified NHL patients in the Swedish Cancer Register 1993 to 2014 and matched comparators from the Swedish Total Population Register. The matched cohort was followed through 2017. By linking to the Swedish Lymphoma Register, subcohort analyses by NHL subtype were performed. Flexible parametric survival models were used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) of SPM among patients and comparators. Among 32\u2009100 NHL patients, 3619 solid tumors and 217 myelodysplastic syndrome (MDS)\/acute myeloid leukemia (AML) cases were observed, corresponding to a 40% higher rate of solid tumors (HRsolid tumors = 1.4; 95% CI, 1.4-1.5) and a 5-fold higher rate of MDS\/AML (HRMDS\/AML = 5.2; 95% CI, 4.4-6.2) than for comparators. Overall, the observed excess risks for solid tumors or MDS\/AML remained stable over the study period, except for follicular lymphoma, where the excess rate of MDS\/AML attenuated with time (P for trend = .012). We conclude that NHL survivors have an increased risk of both solid tumors and hematologic malignancies, in particular MDS\/AML. Stable excess risks over time indicate that contemporary treatment standards are not associated with modified SPM risk. Encouragingly, decreasing rates of MDS\/AML were noted among patients with follicular lymphoma, possibly due to the increasing use of nonchemotherapy-based treatments.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021006369","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T22:07:45Z","timestamp":1642543665000},"page":"2657-2666","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":33,"title":["Incidence and time trends of second primary malignancies after non-Hodgkin lymphoma: a Swedish population-based study"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0795-3659","authenticated-orcid":false,"given":"Joel","family":"Joelsson","sequence":"first","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden;"},{"name":"Department of Hematology, Karolinska University Hospital, Stockholm, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4281-0349","authenticated-orcid":false,"given":"Tove","family":"W\u00e4sterlid","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden;"},{"name":"Department of Hematology, Karolinska University Hospital, Stockholm, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Rosenquist","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden;"},{"name":"Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lasse Hjort","family":"Jakobsen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Aalborg University Hospital, Aalborg, Denmark;"},{"name":"Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; and"},{"name":"Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4406-380X","authenticated-orcid":false,"given":"Tarec C.","family":"El-Galaly","sequence":"additional","affiliation":[{"name":"Department of Hematology, Aalborg University Hospital, Aalborg, Denmark;"},{"name":"Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; and"},{"name":"Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin E.","family":"Smedby","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden;"},{"name":"Department of Hematology, Karolinska University Hospital, Stockholm, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5806-0573","authenticated-orcid":false,"given":"Sandra","family":"Eloranta","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,4,22]]},"reference":[{"issue":"6","key":"2022042215221684900_B1","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjh.16489","article-title":"Trends in the prevalence, incidence and survival of non-Hodgkin lymphoma subtypes during the 21st century \u2013 a Swedish lymphoma register study","volume":"189","author":"Ekberg","year":"2020","journal-title":"Br J Haematol."},{"key":"2022042215221684900_B2","author":"Ekstrom Smedby","year":"2018"},{"issue":"3","key":"2022042215221684900_B3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3816\/CLM.2003.n.025","article-title":"An update of the epidemiology of non-Hodgkin\u2019s lymphoma","volume":"4","author":"Chiu","year":"2003","journal-title":"Clin Lymphoma."},{"issue":"7","key":"2022042215221684900_B4","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1054\/bjoc.1999.1102","article-title":"Second primary neoplasms following non-Hodgkin\u2019s lymphoma in New South Wales, Australia","volume":"82","author":"Brennan","year":"2000","journal-title":"Br J Cancer."},{"issue":"1","key":"2022042215221684900_B5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/sj.bjc.6602654","article-title":"Second primary cancers among 109 000 cases of non-Hodgkin\u2019s lymphoma","volume":"93","author":"Brennan","year":"2005","journal-title":"Br J Cancer."},{"issue":"11","key":"2022042215221684900_B6","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1007\/s00432-015-1979-1","article-title":"Development of second primary malignancy in patients with non-Hodgkin lymphoma: a nationwide population-based study","volume":"141","author":"Chien","year":"2015","journal-title":"J Cancer Res Clin Oncol."},{"issue":"7","key":"2022042215221684900_B7","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1054\/bjoc.2001.1998","article-title":"Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958-1996: a search for common mechanisms","volume":"85","author":"Dong","year":"2001","journal-title":"Br J Cancer."},{"issue":"11","key":"2022042215221684900_B8","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1200\/JCO.2007.14.6068","article-title":"Risk of subsequent solid tumors after non-Hodgkin\u2019s lymphoma: effect of diagnostic age and time since diagnosis","volume":"26","author":"Hemminki","year":"2008","journal-title":"J Clin Oncol."},{"issue":"5","key":"2022042215221684900_B9","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/bjh.12684","article-title":"Age-time risk patterns of solid cancers in 60\u00a0901 non-Hodgkin lymphoma survivors from Finland, Norway and Sweden","volume":"164","author":"Lorenzo Bermejo","year":"2014","journal-title":"Br J Haematol."},{"issue":"33","key":"2022042215221684900_B10","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1200\/JCO.2010.29.1112","article-title":"Second malignancy risks after non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype","volume":"28","author":"Morton","year":"2010","journal-title":"J Clin Oncol."},{"issue":"8","key":"2022042215221684900_B11","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/annonc\/mdq697","article-title":"Risk for second malignancies in non-Hodgkin\u2019s lymphoma survivors: a meta-analysis","volume":"22","author":"Pirani","year":"2011","journal-title":"Ann Oncol."},{"issue":"4","key":"2022042215221684900_B12","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/hon.2302","article-title":"Incidence and epidemiology of non-Hodgkin lymphoma and risk of second malignancy among 22\u2009466 survivors in Israel with 30\u2009years of follow-up","volume":"35","author":"Tadmor","year":"2017","journal-title":"Hematol Oncol."},{"issue":"1","key":"2022042215221684900_B13","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/bjh.14638","article-title":"Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era","volume":"178","author":"Tao","year":"2017","journal-title":"Br J\u00a0Haematol."},{"issue":"1","key":"2022042215221684900_B14","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/cncr.21971","article-title":"The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma","volume":"107","author":"Tward","year":"2006","journal-title":"Cancer."},{"issue":"2","key":"2022042215221684900_B15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/hon.2256","article-title":"Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study","volume":"35","author":"W\u00e4sterlid","year":"2017","journal-title":"Hematol Oncol."},{"issue":"9","key":"2022042215221684900_B16","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1182\/bloodadvances.2020001518","article-title":"Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis","volume":"4","author":"Lepp\u00e4","year":"2020","journal-title":"Blood Adv."},{"issue":"1","key":"2022042215221684900_B17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40164-019-0131-3","article-title":"The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994-2016","volume":"8","author":"Carlsten","year":"2019","journal-title":"Exp Hematol Oncol."},{"key":"2022042215221684900_B18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/JBM.S190784","article-title":"How the discovery of rituximab impacted the treatment of B-cell non-Hodgkin\u2019s lymphomas","volume":"10","author":"Mohammed","year":"2019","journal-title":"J Blood Med."},{"issue":"1","key":"2022042215221684900_B19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.beha.2019.02.008","article-title":"Therapy-related myeloid neoplasms in lymphoma survivors: reducing risks","volume":"32","author":"Al-Juhaishi","year":"2019","journal-title":"Best Pract Res Clin Haematol."},{"issue":"1","key":"2022042215221684900_B20","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/02841860802247664","article-title":"The completeness of the Swedish Cancer Register: a sample survey for year 1998","volume":"48","author":"Barlow","year":"2009","journal-title":"Acta Oncol"},{"issue":"1","key":"2022042215221684900_B21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/00043426-199302000-00013","article-title":"High frequency of etoposide (VP-16)-related secondary leukemia in children with non-Hodgkin\u2019s lymphoma","volume":"15","author":"Sugita","year":"1993","journal-title":"Am J Pediatr Hematol Oncol."},{"issue":"4","key":"2022042215221684900_B22","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1053\/j.seminoncol.2008.04.012","article-title":"Therapy-related myeloid leukemia","volume":"35","author":"Godley","year":"2008","journal-title":"Semin Oncol."},{"issue":"15","key":"2022042215221684900_B23","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/sim.1203","article-title":"Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects","volume":"21","author":"Royston","year":"2002","journal-title":"Stat Med."},{"issue":"3","key":"2022042215221684900_B24","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/annonc\/mdv616","article-title":"Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis","volume":"27","author":"Fleury","year":"2016","journal-title":"Ann Oncol."},{"issue":"17","key":"2022042215221684900_B25","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMra022137","article-title":"Skin cancers after organ transplantation","volume":"348","author":"Euvrard","year":"2003","journal-title":"N Engl J Med."},{"issue":"10","key":"2022042215221684900_B26","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1182\/blood-2005-04-1535","article-title":"Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factors","volume":"106","author":"Hill","year":"2005","journal-title":"Blood."},{"issue":"3","key":"2022042215221684900_B27","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3892\/mco.2016.727","article-title":"Hodgkin\u2019s lymphoma as a rare variant of Richter\u2019s transformation in chronic lymphocytic leukemia: a case report and review of the literature","volume":"4","author":"Janjetovic","year":"2016","journal-title":"Mol Clin Oncol."},{"issue":"2","key":"2022042215221684900_B28","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/annonc\/mdx768","article-title":"Rituximab: a benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomas","volume":"29","author":"Karmali","year":"2018","journal-title":"Ann Oncol."},{"issue":"4","key":"2022042215221684900_B29","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3390\/cancers12041050","article-title":"DNA damage\/repair management in cancers","volume":"12","author":"Alhmoud","year":"2020","journal-title":"Cancers (Basel)."},{"issue":"12","key":"2022042215221684900_B30","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.4065\/mcp.2010.0260","article-title":"Radiation risk from medical imaging","volume":"85","author":"Lin","year":"2010","journal-title":"Mayo Clin Proc."},{"issue":"14","key":"2022042215221684900_B31","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.ejca.2007.07.015","article-title":"Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe","volume":"43","author":"Serraino","year":"2007","journal-title":"Eur J Cancer."},{"issue":"5","key":"2022042215221684900_B32","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/CCO.0000000000000474","article-title":"New insights in the pathogenesis of T-cell lymphomas","volume":"30","author":"Lemonnier","year":"2018","journal-title":"Curr Opin Oncol."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/8\/2657\/1892943\/advancesadv2021006369.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/8\/2657\/1892943\/advancesadv2021006369.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T15:23:04Z","timestamp":1650640984000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/8\/2657\/483555\/Incidence-and-time-trends-of-second-primary"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,22]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,4,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021006369","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,22]]}}}